Treatment of metastatic medullary thyroid cancer drug approved for the U.S. market
Cabozantinib is a kinase inhibitor , can inhibit cell growth and development medulla abnormal protein kinase .
One included 330 cases of patients with medullary thyroid carcinoma clinical trial evaluating the safety and efficacy of Cabozantinib . The results showed that , compared with placebo , Cabozantinib prolong progression-free survival of patients with cancer-free period of up to 8.2 months, and some patients can reduce tumor size. But life in patients receiving Cabozantinib no longer.
Cabozantinib include a boxed warning that the medical staff of this drug in certain patients with severe and fatal bleeding and perforation of the colon .
The most common adverse drug reactions include diarrhea , stomatitis , or ulcers, hand-foot syndrome , weight loss, decreased appetite , nausea , fatigue , mouth pain, hair becomes gray and hair loss, bad taste , new-onset hypertension or worsening abdominal pain and constipation. The most common laboratory abnormalities include elevated liver enzymes , hypocalcemia and hypophosphatemia , white blood cells and platelets .
cabozantinib is the second to be approved for the treatment of medullary thyroid cancer drug , vandetanib is the FDA in April last year, the first drug approved to treat the disease .
Treatment of metastatic medullary thyroid cancer drug approved for the U.S. market
ReplyDeleteCabozantinib is a kinase inhibitor , can inhibit cell growth and development medulla abnormal protein kinase .
One included 330 cases of patients with medullary thyroid carcinoma clinical trial evaluating the safety and efficacy of Cabozantinib . The results showed that , compared with placebo , Cabozantinib prolong progression-free survival of patients with cancer-free period of up to 8.2 months, and some patients can reduce tumor size. But life in patients receiving Cabozantinib no longer.
Cabozantinib include a boxed warning that the medical staff of this drug in certain patients with severe and fatal bleeding and perforation of the colon .
The most common adverse drug reactions include diarrhea , stomatitis , or ulcers, hand-foot syndrome , weight loss, decreased appetite , nausea , fatigue , mouth pain, hair becomes gray and hair loss, bad taste , new-onset hypertension or worsening abdominal pain and constipation. The most common laboratory abnormalities include elevated liver enzymes , hypocalcemia and hypophosphatemia , white blood cells and platelets .
cabozantinib is the second to be approved for the treatment of medullary thyroid cancer drug , vandetanib is the FDA in April last year, the first drug approved to treat the disease .
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
GW 5074
AZ 628
ZM 336372
SP600125
CC-401 HCl
JNK-IN-8
AS 602801
SB 203580
SB 202190
Doramapimod